Knud Kragballe

Knud Kragballe's AcademicInfluence.com Rankings

Knud Kragballe

Medical

#2884

World Rank

#3328

Historical Rank

Dermatology

#60

World Rank

#82

Historical Rank

medical Degrees

Knud Kragballe

Philosophy

#8260

World Rank

#11603

Historical Rank

Logic

#5294

World Rank

#6681

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Knud Kragballe's Degrees

PhD Dermatology University of Copenhagen
Doctorate Medicine University of Copenhagen

Why Is Knud Kragballe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Knud Kragballe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Definition of treatment goals for moderate to severe psoriasis: a European consensus (2010) (729)
[Hereditary angioedema]. (2020) (371)
Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris (1991) (320)
Characterization of the interleukin‐17 isoforms and receptors in lesional psoriatic skin (2009) (302)
Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. (2001) (252)
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris (2011) (243)
Biological therapies in the systemic management of psoriasis: International Consensus Conference (2004) (214)
Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double‐blind study (1988) (202)
Methotrexate induced liver cirrhosis (1980) (197)
The mitogen‐activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin (2005) (183)
Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903) (1989) (178)
Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Modulation of clinical course of psoriatic subjects. (1986) (177)
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. (2003) (173)
Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double‐blind, vehicle‐controlled clinical trial (2002) (156)
Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes (1985) (151)
A 52‐week randomized safety study of a calcipotriol/betamethasone dipropionate two‐compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris (2006) (150)
Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. (1989) (150)
Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21 (2006) (140)
Effects of psychologic intervention on psoriasis: a preliminary report. (1996) (135)
A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis (2014) (126)
Abnormalities in epidermal lipid metabolism in patients with atopic dermatitis. (1991) (123)
Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. (2003) (119)
The dynamics of gene expression of interleukin‐19 and interleukin‐20 and their receptors in psoriasis (2005) (117)
A phase IIIb, multicentre, randomized, double‐blind, vehicle‐controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study (2010) (108)
Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. (1986) (106)
A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. (1989) (105)
Renal biopsy findings in long‐term cyclosporin treatment of psoriasis (1997) (103)
Efficacy of once‐daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris (2004) (102)
Benoxaprofen improves psoriasis. A double-blind study. (1983) (101)
Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. (2010) (100)
Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. (1993) (98)
Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. (1995) (98)
Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. (1990) (97)
Improvements in patient‐reported outcomes in moderate‐to‐severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study (2009) (95)
The activity of caspase-1 is increased in lesional psoriatic epidermis. (2007) (92)
Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. (2015) (92)
Role of oxygen in antibody-dependent cytotoxicity mediated by monocytes and neutrophils. (1980) (91)
Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3‐Ser727 phosphorylation as a modulator of transcriptional activity (2013) (87)
Scalp psoriasis: a review of current topical treatment options (2007) (82)
Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris (2006) (75)
Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. (2012) (72)
The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. (1996) (72)
Treatment of psoriasis with calcipotriol and other vitamin D analogues. (1992) (72)
Topical corticosteroids: mechanisms of action. (1989) (70)
Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis. (2016) (69)
Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. (2006) (69)
HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. (2003) (68)
Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. (2007) (67)
Interleukin‐20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model (2009) (67)
Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes (2004) (67)
Vitamin D analogues in the treatment of psoriasis (1992) (65)
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial (2009) (64)
Eicosanoids in acute and chronic psoriatic lesions: leukotriene B4, but not 12-hydroxy-eicosatetraenoic acid, is present in biologically active amounts in acute guttate lesions. (1989) (64)
Caspase-5 expression is upregulated in lesional psoriatic skin. (2011) (63)
1α,25(OH)2D3 regulates NF-κB DNA binding activity in cultured normal human keratinocytes through an increase in IκBα expression (2004) (62)
Topical corticosteroids in psoriasis: strategies for improving safety (2010) (62)
A low-fat diet supplemented with dietary fish oil (Max-EPA) results in improvement of psoriasis and in formation of leukotriene B5. (1989) (61)
Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis (1994) (61)
Preferential inhibition of the mRNA expression of p38 mitogen‐activated protein kinase regulated cytokines in psoriatic skin by anti‐TNFα therapy (2010) (60)
1,25(OH)2-D3 is a potent regulator of interleukin-1 induced interleukin-8 expression and production. (1991) (60)
Inverse Regulation of the Nuclear Factor-κB Binding to the p53 and Interleukin-8 κB Response Elements in Lesional Psoriatic Skin (2005) (59)
Significance of leukotriene-A4 hydrolase in the pathogenesis of psoriasis. (1997) (59)
Improvement of psoriasis vulgaris after intralesional injections of 15-hydroxyeicosatetraenoic acid (15-HETE). (1988) (57)
Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro (1985) (57)
Inhibition by leukotriene B5 of leukotriene B4-induced activation of human keratinocytes and neutrophils. (1987) (55)
Juvenile psoriasis and its clinical management: a European expert group consensus (2010) (55)
Kinetics and differential expression of the skin‐related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis (2011) (54)
Consistency of data in six phase III clinical studies of a two‐compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis (2006) (54)
Dermis-derived 15-hydroxy-eicosatetraenoic acid inhibits epidermal 12-lipoxygenase activity. (1986) (54)
Development of bullous pemphigoid during treatment of psoriasis with adalimumab (2009) (53)
Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase. (1993) (53)
Arachidonic acid and leukotrienes in dermatology. (1983) (53)
15-Hydroxy-eicosatetraenoic acid (15-HETE) inhibits carrageenan-induced experimental arthritis and reduces synovial fluid leukotriene B4 (LTB4). (1989) (51)
IL-20 gene expression is induced by IL-1β through mitogen-activated protein kinase and NF-κB-dependent mechanisms (2007) (51)
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study (2013) (51)
15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits LTB4-induced chemotaxis of human neutrophils. (1988) (49)
Aldara®‐induced skin inflammation: studies of patients with psoriasis (2015) (49)
1alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expression in human keratinocytes. (2003) (49)
Enkephalins modulate differentiation of normal human keratinocytes in vitro (1997) (48)
Calcipotriol: a new drug for topical psoriasis treatment. (1995) (48)
Eicosanoids in inflammatory skin diseases. (2000) (48)
Vitamin D3 analogues. (1997) (47)
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus (2006) (47)
Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis. (1987) (47)
Atopic Dermatitis and Risk of Skin Cancer (2012) (46)
Tumor Necrosis Factor α-Mediated Induction of Interleukin 17C in Human Keratinocytes Is Controlled by Nuclear Factor κB (2011) (45)
Pro‐inflammatory cytokine release in keratinocytes is mediated through the MAPK signal‐integrating kinases (2008) (45)
The p38 MAPK Regulates IL-24 Expression by Stabilization of the 3′ UTR of IL-24 mRNA (2010) (45)
Arachidonic acid metabolism in skin health and disease. (2000) (44)
Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens. (1992) (44)
Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. (2007) (43)
Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes. (2000) (42)
Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting (2011) (42)
1α, 25-dihydroxyvitamin D3 induced differentiation of cultured human keratinocytes is accompanied by a PKC-independent regulation of AP-1 DNA binding activity (2000) (42)
MK2 regulates the early stages of skin tumor promotion. (2009) (40)
1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. (2004) (39)
Evaluation of recurrence after photodynamic therapy with topical methylaminolaevulinate for 157 basal cell carcinomas in 90 patients. (2012) (39)
Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. (1988) (39)
Methotrexate in psoriatic arthritis: a retrospective study. (1983) (39)
Proliferation and differentiation of cultured human keratinocytes is modulated by 1,25(OH)2D3 and synthetic vitamin D3 analogues in a cell density-, calcium- and serum-dependent manner. (1997) (38)
Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway (2004) (38)
Two cases of atopic dermatitis‐like conditions induced in psoriasis patients treated with infliximab (2007) (38)
In vitro synthesis of 12-hydroxy-eicosatetraenoic acid is increased in uninvolved psoriatic epidermis. (1986) (38)
Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial (2009) (37)
Upregulation of vitamin D receptor levels by 1,25(OH)2 vitamin D3 in cultured human keratinocytes (1997) (37)
A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease. (1992) (37)
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. (2006) (37)
Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. (2013) (37)
Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. (2009) (36)
Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. (1997) (36)
Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. (1991) (36)
Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous disease. (1981) (35)
One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis (2014) (34)
Adalimumab therapy rapidly inhibits p38 mitogen‐activated protein kinase activity in lesional psoriatic skin preceding clinical improvement (2010) (34)
Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin (2004) (34)
Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. (2013) (34)
IL-20 gene expression is induced by IL-1beta through mitogen-activated protein kinase and NF-kappaB-dependent mechanisms. (2007) (34)
New vitamin D analogs in psoriasis. (2004) (33)
A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. (1991) (33)
Psoriasis: consensus on topical therapies (2008) (33)
Lysophosphatidylcholine: a chemoattractant to human T lymphocytes (2004) (33)
Increased lysophosphatidylcholine content in lesional psoriatic skin (1995) (33)
Antibodies to the Borrelia burgdorferi flagellum in patients with scleroderma, granuloma annulare and porphyria cutanea tarda. (1989) (32)
IL-8 and p53 are inversely regulated through JNK, p38 and NF-κB p65 in HepG2 cells during an inflammatory response (2008) (32)
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment (2006) (32)
Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis (2014) (31)
IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. (2013) (30)
Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophilsin vitro. Evidence of formation of antiinflammatory compounds (1991) (30)
Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. (2005) (30)
A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity (2005) (30)
Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13. (1995) (30)
Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression (2011) (30)
Recent developments in vitamin D analogs. (2000) (29)
Serum beta 2-microglobulin in acute and chronic leukaemia. (2009) (29)
Twenty-nail dystrophy treated with topical PUVA. (1990) (29)
Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. (1994) (28)
Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. (1993) (27)
Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails. (2009) (27)
The monocyte as a model for the study of insulin receptors in man (1977) (27)
Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases (2009) (27)
Mice Lacking MSK1 and MSK2 Show Reduced Skin Tumor Development in a Two-Stage Chemical Carcinogenesis Model (2011) (27)
Calcipotriol. A new topical antipsoriatic. (1993) (27)
Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1–7 (1995) (27)
Selective decrease of 15-hydroxyeicosatetraenoic acid (15-HETE) formation in uninvolved psoriatic dermis. (1986) (27)
Histiocytosis X–an immune deficiency disease? Studies on antibody‐dependent monocyte‐mediated cytotoxicity (1981) (26)
Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis (2002) (26)
Pharmacokinetics and Therapeutic Efficacy of Retinoids in Skin Diseases (1992) (25)
Enkephalin-like immunoreactivity in human skin is found selectively in a fraction of CD68 – positive dermal cells: increase in enkephalin-positive cells in lesional psoriasis (1997) (24)
Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. (1997) (24)
Lysophosphatidylcholine induces keratinocyte differentiation and upregulation of AP-1- and NF-kappaB DNA-binding activity. (2004) (23)
The Pharmacokinetics of Acitretin and its 13‐cis‐metabolite in Psoriatic Patients (1991) (23)
KID Syndrome: report of a Scandinavian patient with connexin-26 gene mutation. (2005) (23)
Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. (2001) (23)
Purification and characterization of leukotriene A4 hydrolase from human epidermis (1995) (23)
Enhanced monocyte and neutrophil cytotoxicity and normal cyclic nucleotide levels in severe psoriasis (1981) (23)
The future of vitamin D in dermatology. (1997) (22)
Colchicine in generalized pustular psoriasis: Clinical response and antibody-dependent cytotoxicity by monocytes and neutrophils (2004) (22)
On the mechanism of enhanced monocyte and neutrophil cytotoxicity in severe psoriasis. (1982) (22)
Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp (2014) (22)
Transition to ustekinumab in patients with moderate‐to‐severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) (2014) (22)
Increased aggregation and arachidonic acid transformation by psoriatic platelets: evidence that platelet-derived 12-hydroxy-eicosatetraenoic acid increases keratinocyte DNA synthesis in vitro (2004) (22)
In vitro inhibition of leukotriene B4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils (2004) (21)
Vitamin D 3 Analogues (1995) (21)
Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. (1985) (21)
Unmet needs in the treatment of psoriasis (2014) (21)
The role of mitogen‐ and stress‐activated protein kinase 1 and 2 in chronic skin inflammation in mice (2011) (21)
Dietary supplementation with a combination of n-3 and n-6 fatty acids (super gamma-oil marine) improves psoriasis. (1989) (21)
Psoriasis and other skin diseases. (1997) (20)
Tumour necrosis factor‐α plays a significant role in the Aldara‐induced skin inflammation in mice (2016) (20)
Signal Transduction Pathways in the Skin (2004) (20)
Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council (2011) (20)
Supplementation with evening primrose oil in atopic dermatitis: Effect on fatty acids in neutrophils and epidermis (1991) (20)
Impaired Monocyte Cyclic AMP Responses and Monocyte Cytotoxicity in Atopic Dermatitis (1980) (20)
Changes in lipoxygenase products from synovial fluid in carragheenan induced arthritis in dogs (1988) (20)
The expression of dual‐specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin (2013) (20)
Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism (2004) (20)
Eicosanoids in psoriasis--15-HETE on the stage. (1987) (19)
Long-term management of scalp psoriasis: perspectives from the international psoriasis council (2013) (19)
Reduced neutrophil LTB4 release in atopic dermatitis patients despite normal fatty acid composition. (1991) (18)
An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals (2013) (18)
Normal levels of the vitamin D receptor and its message in psoriatic skin. (1996) (18)
Effects of vitamin D3 on keratinocyte proliferation and differentiation in vitro: modulation by ligands for retinoic acid and retinoid X receptors. (1997) (18)
Interleukin-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: in vitro anti-inflammatory effects by interleukin-4 and interleukin-10, but not by interleukin-1 receptor antagonist protein. (1994) (18)
Signal transduction pathways in human epidermis. (2005) (18)
Lack of transmission of Borrelia burgdorferi by blood transfusion (1990) (18)
ATP-ase activity of purified human normal T- and B-lymphocytes. (2009) (18)
Experience of Being Young With Psoriasis: Self-Management Support Needs (2018) (17)
Vitamin D and UVB radiation therapy. (2002) (17)
Histologic changes in the liver during etretinate treatment. (1984) (17)
Identification and subcellular localization of leukotriene A4-hydrolase activity in human epidermis. (1993) (17)
Heterogeneous distribution of lipoxygenase products in psoriatic skin lesions (2004) (17)
Antibody‐Dependent Monocyte‐Mediated Cytotoxidty in Severe Atopic Dermatitis (1979) (16)
Formation of epidermal cell thymocyte-activating factor (ETAF) from cultured human keratinocytes from normal and uninvolved psoriatic skin. (1987) (16)
Vitamin D3 and skin diseases (2004) (15)
The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin (2009) (15)
Interaction of Etretinate with Methotrexate Pharmacokinetics in Psoriatic Patients (1990) (15)
Interleukin-8 stimulates the formation of 15-hydroxy-eicosatetraenoic acid by human neutrophilsin vitro (1992) (15)
Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-O-tetradecanoylphorbol 13-acetate. (2011) (13)
Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. (1987) (13)
CCL27 expression is regulated by both p38 MAPK and IKKβ signalling pathways. (2011) (13)
Modulation of epidermal cell division and growth by oxygenation products of arachidonic acid. (1984) (13)
Flow-cytometric investigation of epidermal cell characteristics in monogenic disorders of keratinization and their modulation by topical calcipotriol treatment. (1996) (12)
Immunosuppressive therapy in dermatology and PML (2009) (12)
Arachidonic acid and leukotrienes in clinical dermatology. (1985) (12)
Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark (2007) (12)
Efficacy and safety of the 20-epi-vitamin D3 analogue KH 1060 in the topical therapy of psoriasis: results of a dose-ranging study. (1994) (12)
15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits the LTB4-induced skin response (2004) (12)
Arachidonic acid in psoriasis. Pathogenic role and pharmacological regulation. (1985) (12)
Liver Biopsy during Etretinate (Tigason®) Treatment (1985) (12)
Recommendations for the topical treatment of psoriasis (2005) (11)
Implementing best practice in psoriasis: a Nordic expert group consensus. (2014) (11)
Incorporation of 15‐hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques (1995) (11)
Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. (1996) (11)
Distribution of monohydroxy fatty acids in specific human epidermal phospholipids (1993) (11)
Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin (2014) (11)
Oral acitretin in psoriasis: drug and vitamin A concentrations in plasma, skin and adipose tissue. (1992) (11)
Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules (2016) (10)
HLA antigens in methotrexate-induced liver cirrhosis. (1980) (10)
Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts (2009) (10)
15-HETE inhibits leukotriene B4 formation and synovial cell proliferation in experimental arthritis (2005) (10)
Decrease in Enkephalin Levels in Psoriatic Lesions after Calcipotriol and Mometasone Furoate Treatment (1999) (10)
Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis (2017) (10)
Monohydroxy fatty acids esterified to phospholipids are decreased in lesional psoriatic skin (2004) (10)
1alpha,25-dihydroxyvitamin D3 induced differentiation of cultured human keratinocytes is accompanied by a PKC-independent regulation of AP-1 DNA binding activity. (2000) (10)
Synovitis reduced by inhibition of leukotriene B4. Carrageenan-induced gonarthritis studied in dogs. (1990) (10)
Sustained depression of monocyte cytotoxicity in a boy with disseminated nontuberculous mycobacteriosis. (1981) (9)
Inhibition of the 1,25-dihydroxyvitamin D3-induced increase in vitamin D receptor (VDR) levels and binding of VDR-retinoid X receptor (RXR) to a direct repeat (DR)-3 type response element by an RXR-specific ligand in human keratinocyte cultures. (1998) (9)
Climatotherapy at the Dead Sea stimulates vitamin D3 metabolism. (1996) (9)
Monocyte cytotoxicity after splenectomy. (2009) (9)
IMMUNOPROLIFERATIVE ALTERATIONS IN LYMPHOID TISSUES AND LIVER IN MICE STIMULATED WITH CORYNEBACTERIUM PARVUM (1978) (8)
Effect of intradermal injection of methionine-enkephalin on human skin. (1999) (8)
Divergent effects of methylxanthines and adenylate cyclase agonists on monocyte cytotoxicity and cyclic AMP levels (1982) (8)
INTRALESIONAL INJECTION OF 15 (S)-HYDROXYEICOSATETRAENOIC ACID IN PSORIASIS (1986) (8)
Vitamin D in Dermatology (2000) (8)
Transfer factor in atopic dermatitis. (1982) (7)
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines (2013) (7)
Calcipotriol for psoriasis (1991) (7)
Treatment of treatment‐resistant autoimmune blistering skin disorders with rituximab (2009) (7)
Antibody-dependent monocyte-mediated cytotoxicity. Serial studies in acute myeloid leukaemia. (2009) (7)
Antibody-dependent monocyte-mediated cytotoxicity. The interference by platelets, immune complexes, and normal serum. (2009) (7)
Transient cyclic AMP accumulation during antibody-dependent cytotoxicity mediated by monocytes and neutrophils. (1981) (7)
Mechanisms of decreased antibody-dependent cytotoxicity mediated by monocytes and neutrophils in atopic dermatitis. (1981) (7)
Liver biopsy in PUVA-treated patients. (1979) (6)
All‐trans retinoic acid inhibits binding of 1,25‐dihydroxy‐vitamin D3 to the vitamin D receptor in cultured human keratinocytes (1996) (6)
Modulation of eicosanoid formation by lesional skin of psoriasis: an ex vivo skin model. (1993) (6)
The oxygen-dependent antibody-dependent cell-mediated cytotoxicity of human monocytes and neutrophils. (1982) (6)
Normalization of monocyte chemotaxis precedes clinical resolution of psoriasis treated with benoxaprofen. (1985) (6)
Mass spectrometry of underivatized 15-hydroxyeicosatetraenoic acid and 15-hydroxyeicosapentaenoic acid. (1988) (6)
[Permanent hair loss after Kerion Celsi]. (1991) (5)
Transcriptional Activation by 1,25-Dihydroxyvitamin D3 and Synthetic Vitamin D3 Analogues in Transfected Cultures of Human Keratinocytes (1997) (5)
Studies of peripheral blood monocytes in pulmonary sarcoidosis. (1984) (5)
Vitamin D3 analogues. (1995) (5)
Monocyte-mediated antibody-dependent cytotoxicity. Modulation by Glycolysis and insulin. (2009) (4)
Effect of auranofin on eicosanoids and protein kinase C in human neutrophils (1989) (4)
Facilitation of cAMP increments during ADCC mediated by monocytes pretreated with cAMP-elevating agents. (1983) (4)
1a, 25(OH)2D3 stimulates AP-1 DNA binding activity by a PI3-kinase/Ras/MEK/ERK1/2 and JNK1 dependent increase in c-Fos, Fra1 and c-Jun expression in human keratinocytes (2003) (4)
Multiple bites from the larvae of the tick Ixodes ricinus. A case report. (1989) (4)
EFFECT OF CALCIPOTRIOL ON PSORIASIS: A DOUBLE BLIND PLACEBO CONTROLLED STUDY OF CALCIPOTROL ( MC903) AND CALCIUM METABOLISM (1991) (4)
Arachidonic acid metabolism in skin (1999) (4)
Proliferation of adherent synovial fluid cell cultures is modified by eicosanoids (1990) (3)
AP-1 DNA binding activity is significantly reduced in involved psoriatic skin In vitro and in vivo regulation of AP-1 DNA binding activity by 1alpha,25 2D3 and calcipotriol (2000) (3)
Vitamin D3 analogues in psoriasis. (1990) (3)
Caring for young people with moderate to severe psoriasis: an interpretive description of parental perspectives (2020) (3)
Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis. (1989) (3)
Monohydroxy fatty acids in specific epidermal phospholipids: Depletion in lesional psoriatic skin (1993) (3)
Antibody‐Dependent Monocyte‐Mediated Cytotoxicity in Atopic Dermatitis (1981) (3)
LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin (1996) (3)
Increased ATP-ase activity of lymphocytes after rosette formation with sheep red blood cells. (2009) (3)
Impaired monocyte-mediated cytotoxicity in atopic dermatitis (2004) (2)
EFFICACY AND TOLERABILITY OF CALCIPOTRIOL IN PSORIASIS (1991) (2)
[Renal biopsy in connection with long-term treatment of psoriasis with cyclosporine]. (1998) (2)
Vitamin D : actions and applications in dermatology : ESDR Clinically Orientated Symposium, Aarhus, Denmark, April 28-29, 1995 (1996) (2)
Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity? (2007) (2)
Chemotactic lipoxygenase products in sera from patients with psoriasis (2004) (2)
An innovation in topical therapy: insights from international dermatologists. (2007) (2)
LTA 4 hydrolase in human skin : decreased activity , but normal concentration in lesional psoriatic skin Evidence for different LTA 4 hydrolase activity in human lymphocytes and human skin (2)
A highly effective once daily treatment with a new two-compound calcipotriene/betamethasone dipropionate ointment in psoriasis vulgaris (2004) (2)
[Polyunsaturated fatty acid preparations available on the Danish market. Composition and oxidative stability]. (1990) (2)
Changes in renal biopsies during low dosage cyclosporin treatment. (1990) (1)
Modulators of cutaneous inflammation and proliferation in psoriasis. (1989) (1)
Antibody-Dependent Monocyte-Mediated Cytotoxicity: The Effects of Adherence and Removal of Mononuclear Phagocytic Cells, and of in vitro Incubation (2009) (1)
Stimulation of monocyte-mediated, antibody-dependent cytotoxicity in mycosis fungoides. (1983) (1)
10th Symposium on Advances in Skin Pharmacology—CIRD GALDERMA. “From Molecular Biology to Therapeutics,” Sophia Antipolis, October 1st to 3rd, 1992 (1993) (1)
Cyclosporin versus methotrexate toxicity in psoriasis (1990) (1)
Upregulation of 1,25-dihydroxyvitamin D3-receptor (VDR) expression, and modulation of markers for proliferation, differentiation and inflammation in calcipotriol (MC 903) treated psoriatic skin (1993) (1)
Lipoxygenase products in experimental septic arthritis in dogs (1988) (1)
Efficacy of once daily application of a new two-compound calcipotriene/betamethasone dipropionate ointment in extensive psoriasis (2004) (1)
Specific hyposensitization and non-specific immunotherapy in severe atopic dermatitis (1984) (1)
Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of T-cells (1998) (1)
Abnormal 15-hydroxyeicosatetraenoic acid (15-HETE) formation in psoriatic dermis. (1987) (1)
[Methotrexate-induced liver cirrhosis in psoriasis. Determination of tissue type and histopathological assessment]. (1980) (1)
The vitamin D receptor mRNA and protein is normal in psoriatic skin (1994) (1)
EXOTIC BUTTERS AS COSMETIC LIPIDS (1998) (1)
Growth medium-dependent ERK1/2 and AP-1 activity in cultured normal human keratinocytes modulates 1α,25-dihydroxyvitamin D3-induced differentiation (2003) (1)
[Biological treatment of psoriasis and psoriatic arthritis]. (2008) (1)
Contents Vol. 213, 2006 (2006) (0)
Immunsuppression in der Dermatologie und PML (2009) (0)
The efficacy and tolerability of topical calcipotriol in psoriasis vulgaris (1993) (0)
[Molecular biology within dermatology]. (1996) (0)
How to manage the impatient patient (1998) (0)
[Calcipotriol--a new agent for local treatment of psoriasis]. (1991) (0)
Eicosanoids in Dermatology (1988) (0)
Long-term efficacy of a calcipotriol/betamethasone dipropionate two-compound product in psoriasis vulgaris (2006) (0)
Contents Vol. 210, 2005 (2005) (0)
Vitamin D analogs in dermatology : proceedings from the first North American Calcipotriene/Calcipotriol Symposium, Vancouver, British Columbia, Canada, May 18, 1996 (1997) (0)
Therapy of psoriasis: new horizons. (1986) (0)
Acknowledgement to Referees for Dermatology 2006 (2006) (0)
Treatment of plaque psoriasis (2014) (0)
Anti-inflammatory action of interleukin 13 on the cytokine and arachidonic acid metabolism (1994) (0)
[Erythema multiforme and Stevens-Johnson syndrome are not variants of the same disease]. (1996) (0)
C alcipotriol Ointment i n D isorders o f Keratinizatio n Results of a Randomized, Double-blind, Vehicle-Controlled, Right/Left Comparative Study (1995) (0)
The levels of lysophosphatidylcholine, a chemoattractant to human T-lymphocytes, are increased in lesional psoriatic skin (1994) (0)
Level by MAPK-Activated Protein Kinase 2 Skin Is Regulated at a Posttranscriptional in Psoriatic a Protein Expression of TNF-Lars (2006) (0)
13th International Workshop on Langerhans Cells, LC2013, 10-13 October 2013, Amsterdam, The Netherlands (2013) (0)
The effect of intradermal injection of methionine-enkephalin in normal skin and in a delayed type skin hypersensitivity reaction (1998) (0)
[Drug induced photosensitivity]. (1983) (0)
[Everybody talks about allergy, but who is doing anything against it?]. (1999) (0)
PSS45 Treatment Patterns, Treatment Satisfaction, Disease Severity and Quality of Life in Patients with Psoriasis in Denmark, Finland, and Sweden (2011) (0)
Collagen metabolism in normal human skin after application of calcipotriol: Stimulation of the aminoteminal propeptide of type III procollagen (PIINP), but potentiation of the corticosteroid-induced inhibition of PIIINP (1994) (0)
Calcium efflux changes in neutrophils from patients with severe atopic dermatitis. (1985) (0)
Identification of vitamin D responding genes in keratinocyte cultures by differential display (1998) (0)
Migration of langerhans cells and maturation of their peripheral blood precursors are stimulated by vitamin D3 in normal and psoriatic skin xenotransplants (1998) (0)
Vitamin D -- future perspectives (1995) (0)
Vitamin D3 analogues in psoriasis. Reply (1990) (0)
CGRP in psoriasis (1991) (0)
Changes in renal biopsies during low dosage cyclosporin A (1992) (0)
Dendritic cell migration in psoriasis: is interleukin 20 a key player? (2009) (0)
Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis (2004) (0)
Detection of both active and inactive human leukotriene A4 hydrolase by isoelectric gelelectrophoresis (1998) (0)
PSS28 Long-Term Improvement in Patient-Reported Outcomes After Transition From Methotrexate to Ustekinumab in Moderate to Severe Psoriasis: Transit Week 52 Results (2012) (0)
Modulation of interleukin-8 secretion and eicosanoid metabolism in cultured synovial fluid mononuclear cells from psoriatic arthritis by interleukin-4 and interleukin-10 (1993) (0)
[Treatment of psoriasis]. (1993) (0)
[Biological dermatologic agents. The Danish Society of Dermatology]. (2007) (0)
Etretinate therapy and immune reactivity (2004) (0)
Antibody-Dependent Monocyte-Mediated Cytotoxicity: Isolation and Identification by Esterase Staining of Human Monocytes Detached from Monolayers by Lowering the Temperature (2009) (0)
Nordic Psoriasis Debate 2011: Managing Psoriasis - How Can I Improve Care for my Patients? An Interactive Debate on New Treatment Options for Psoriasis (2012) (0)
[Quality and documentation prior to dermatological laser treatment]. (2005) (0)
Monocyte cytotoxicity in clinical exacerbation and remission of atopic dermatitis (1980) (0)
Cost of psoriasis and psoriatic arthritis in Denmark (2012) (0)
748 Topical application of a platelet activating factor (PAF-) antagonist in atopic eczema (1996) (0)
Application of the vitamin D3 analogue calcipotriol to normal human skin suppresses the number and activity of epidermal Langerhans cells (1994) (0)
Contents, Vol. 164, 1982 (1982) (0)
Subject Index Vol. 213, 2006 (2006) (0)
Subject Index Vol. 210, 2005 (2005) (0)
[Bacillary angiomatosis, cat-scratch disease and trench fever: are these diseases caused by the same bacteria?]. (1996) (0)
Monohydroxyeicosatetraenoic acids are the major lipoxygenase compounds produced by normal human epidermis (1984) (0)
Role of eicosanoids in psoriasis and atopic skin diseases (1999) (0)
PSS21 Treatment Patterns, Costs and Quality of Life in Patients With Plaque Psoriasis in Denmark (2011) (0)
Leukotriene A4 hydrolase, a target for inhibition of leukotriene B4 formation in the epidermis in psoriasis (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Knud Kragballe?

Knud Kragballe is affiliated with the following schools:

Aarhus University

Knud Kragballe's Academic­Influence.com Rankings

Knud Kragballe's Degrees

Why Is Knud Kragballe Influential?

Knud Kragballe's Published Works

Published Works

What Schools Are Affiliated With Knud Kragballe?

Knud Kragballe's AcademicInfluence.com Rankings